D. E. Shaw & Co., Inc. Atreca, Inc. Transaction History

D. E. Shaw & Co., Inc.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$1.59 - $2.74 $374,867 - $645,998	-235,766 Reduced 64.78%	128,168 $201,000
Q2 2022 Aug 15, 2022	BUY	$1.56 - $3.25 $67,020 - $139,626	42,962 Added 13.38%	363,934 $651,000
Q1 2022 May 16, 2022	BUY	$1.61 - $5.2 $270,463 - $873,548	167,990 Added 109.81%	320,972 $1.02 Million
Q4 2021 Feb 14, 2022	BUY	$2.87 - $6.29 $364,375 - $798,578	126,960 Added 487.89%	152,982 $464,000
Q3 2021 Nov 15, 2021	BUY	$4.91 - $9.07 $61,507 - $113,619	12,527 Added 92.83%	26,022 $162,000
Q2 2021 Aug 16, 2021	BUY	$7.82 - $13.8 $105,530 - $186,231	13,495 New	13,495 $115,000

30.6K

Ticker BCEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,876,000
Description
Atreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-10...

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.